OTLK Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Outlook Therapeutics's net margin of -49.65%. Outlook Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Outlook Therapeutics has a consensus price target of --, signalling upside risk potential of 1587.08%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that Outlook Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Outlook Therapeutics is more attractive than NovaBay Pharmaceuticals.

Outlook Therapeutics has a beta of 0.463, which suggesting that the stock is 53.7% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Outlook Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Outlook Therapeutics's net income of $44.4M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 2.97x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Outlook Therapeutics's net margin of 25.23%. Outlook Therapeutics's return on equity of -- beat Pfizer's return on equity of 4.63%.

Outlook Therapeutics has a consensus price target of --, signalling upside risk potential of 1587.08%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Outlook Therapeutics has higher upside potential than Pfizer, analysts believe Outlook Therapeutics is more attractive than Pfizer.

Outlook Therapeutics has a beta of 0.463, which suggesting that the stock is 53.7% less volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Outlook Therapeutics pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Outlook Therapeutics quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Outlook Therapeutics's net income of $44.4M is lower than Pfizer's net income of $4.5B. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 2.97x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Outlook Therapeutics's net margin of -2357.27%. Outlook Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Outlook Therapeutics has a consensus price target of --, signalling upside risk potential of 1587.08%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Outlook Therapeutics, analysts believe Palatin Technologies is more attractive than Outlook Therapeutics.

Outlook Therapeutics has a beta of 0.463, which suggesting that the stock is 53.7% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Outlook Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Outlook Therapeutics's net income of $44.4M is higher than Palatin Technologies's net income of -$7.8M. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 2.97x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Outlook Therapeutics's net margin of --. Outlook Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Outlook Therapeutics has a consensus price target of --, signalling upside risk potential of 1587.08%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 5042.05%. Given that Theriva Biologics has higher upside potential than Outlook Therapeutics, analysts believe Theriva Biologics is more attractive than Outlook Therapeutics.

Outlook Therapeutics has a beta of 0.463, which suggesting that the stock is 53.7% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Outlook Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Outlook Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Outlook Therapeutics's net income of $44.4M is higher than Theriva Biologics's net income of -$7.7M. Notably, Outlook Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics is 2.97x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.